Depakote Tablet, Extended Release
NDC Package 0074-7402-13

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Depakote (divalproex sodium) tablets is a medication used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. This formulation utilizes a tablet, extended release delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-7402 and is authorized under FDA application NDA021168.

Identification & Billing

NDC Package Code
0074-7402-13
Package Description
100 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
0074-7402
11-Digit Billing Format
00074740213
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 1099563 - divalproex sodium 250 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1099563 - 24 HR divalproex sodium 250 MG Extended Release Oral Tablet
  • RxCUI: 1099563 - divalproex sodium 250 MG 24 HR Extended Release Oral Tablet
  • RxCUI: 1099565 - Depakote ER 250 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1099565 - 24 HR divalproex sodium 250 MG Extended Release Oral Tablet [Depakote]

Clinical Specifications

Proprietary Name
Depakote ER
Non-Proprietary Name
Divalproex Sodium
Substance Name
Divalproex Sodium
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DIVALPROEX SODIUM 500 mg/1
Pharmacologic Class
Usage Information
This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA021168
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-04-2000
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-7402-13 identifies a specific commercial package of 100 tablet, extended release in 1 bottle of Depakote ER, a human prescription drug labeled by Abbvie Inc.. This tablet, extended release is formulated for oral use and contains divalproex sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on August 04, 2000. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074740213. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-7402-13
11-Digit CMS (5-4-2)
00074-7402-13

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.